December 2024 in “Indian Journal of Dermatology Venereology and Leprology” Atypical male hair loss may not respond to usual treatments.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This source describes SH‑1 as a next-generation androgen receptor antagonist designed for localized treatment of androgenetic alopecia, aiming to reverse follicular miniaturization while maintaining endocrine balance. Unlike traditional therapies, SH‑1 offers tissue-specific action, avoiding systemic effects.
June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)” This article presents the SH-1 molecule as a novel AR antagonist for androgenetic alopecia treatment, highlighting its tissue-specific action and potential for commercialization, but provides no new clinical results.
This study found significant cephalometric changes in patients with skeletal Class III malocclusion treated with rapid maxillary expansion and reverse traction, demonstrating maxilla advancement and improved facial convexity.
87 citations
,
March 2011 in “Australasian Journal of Dermatology” This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.